In this phase 2 basket trial, patients with heavily pretreated HER2-mutated metastatic breast cancer received the small-molecule HER2 inhibitor tucatinib and anti-HER2 trastuzumab, leading to encouraging clinical response rates.
- Alicia F. C. Okines
- Giuseppe Curigliano
- Paula R. Pohlmann